Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
Sarsia Seed provides follow-up funding for APIM Therapeutics

Sarsia Seed provides follow-up funding for APIM Therapeutics

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

New study finds liver instead of the brain as source of Alzheimer’s plaques

New study finds liver instead of the brain as source of Alzheimer’s plaques

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Researchers identify cell of origin for sarcoma

Researchers identify cell of origin for sarcoma

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx's bafetinib helps reduce skeletal complications in cancer patients

Scientists reprogram marrow cells from patient with chronic myeloid leukemia

Scientists reprogram marrow cells from patient with chronic myeloid leukemia

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

John Theurer Cancer Center presents research findings at ASH meeting

John Theurer Cancer Center presents research findings at ASH meeting

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.